journal
MENU ▼
Read by QxMD icon Read
search

Thrombosis Research

journal
https://www.readbyqxmd.com/read/27890308/erratum-to-a-combined-deficiency-of-tissue-factor-and-par-4-is-associated-with-fatal-pulmonary-hemorrhage-in-mice-thromb-res-146-2016-46-50
#1
Michael F Bode, Nigel Mackman
No abstract text is available yet for this article.
November 24, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27886530/choosing-wisely-the-impact-of-patient-selection-on-efficacy-and-safety-outcomes-in-the-einstein-dvt-pe-and-amplify-trials
#2
Jan Beyer-Westendorf, Anthonie W A Lensing, Roopen Arya, Henri Bounameaux, Alexander T Cohen, Philip S Wells, Saskia Middeldorp, Peter Verhamme, Rodney Hughes, Nils Kucher, Akos F Pap, Mila Trajanovic, Martin H Prins, Paolo Prandoni, Jeffrey I Weitz
BACKGROUND: The results of the EINSTEIN-DVT/PE and AMPLIFY trials, which compared rivaroxaban and apixaban with conventional anticoagulation therapy for acute venous thromboembolism (VTE), respectively, are often compared. However, the trials differed in duration of therapy (3-12 and 6months, respectively) and in patient selection (few exclusion criteria and more stringent exclusion criteria, respectively). METHODS: To determine the effect of these methodological differences on outcomes, the patients enrolled in EINSTEIN-DVT/PE were divided into 2 cohorts; the 5253 patients that matched the exclusion criteria for AMPLIFY and were treated for at least 6months (cohort 1) and the 2368 patients who would have been ineligible for AMPLIFY (cohort 2)...
November 21, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27888769/a-first-described-case-of-cancer-associated-non-bacterial-thrombotic-endocarditis-in-the-era-of-direct-oral-anticoagulants
#3
LETTER
F Mantovani, A Navazio, A Barbieri, G Boriani
No abstract text is available yet for this article.
November 20, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27886531/coagulation-and-sepsis
#4
REVIEW
Marcel Levi, Tom van der Poll
Severe sepsis is almost invariably associated with systemic activation of coagulation. There is ample evidence that demonstrates a wide-ranging cross-talk between hemostasis and inflammation, which is probably implicated in the pathogenesis of organ dysfunction in patients with sepsis. Inflammation not only leads to initiation and propagation of coagulation activity, but coagulation also markedly influences inflammation. Molecular mechanisms that play a role in inflammation-induced effects on coagulation have been recognized in much detail...
November 19, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27902939/factor-xiii-deficiency-enhances-thrombin-generation-due-to-impaired-fibrin-polymerization-an-effect-corrected-by-factor-xiii-replacement
#5
Hanna H Pitkänen, Annukka Jouppila, Marja Lemponen, Minna Ilmakunnas, Jouni Ahonen, Riitta Lassila
INTRODUCTION: Factor XIII (FXIII) cross-links fibrin, completing blood coagulation. Congenital FXIII deficiency is managed with plasma-derived FXIII (pdFXIII) or recombinant FXIII (rFXIII) concentrates. AIM: As the mechanisms protecting patients with low FXIII levels (<5IU/dL) from spontaneous bleeds remain unknown we assessed the interplay between thrombin generation (TG), fibrin formation and clot kinetics before and after FXIII administration in three patients with FXIII deficiency...
November 16, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27855295/establishment-of-a-bleeding-score-as-a-diagnostic-tool-for-patients-with-rare-bleeding-disorders
#6
Roberta Palla, Simona M Siboni, Marzia Menegatti, Khaled M Musallam, Flora Peyvandi
INTRODUCTION: Bleeding manifestations among patients with rare bleeding disorders (RBDs) vary significantly between disorders and patients, even when affected with the same disorder. In response to the challenge represented by the clinical assessment of the presence and severity of bleeding symptoms, a number of bleeding score systems (BSSs) or bleeding assessment tools (BATs) were developed. The majority of these were specifically developed for patients with more common bleeding disorders than RBDs...
November 14, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27865966/febuxostat-attenuates-paroxysmal-atrial-fibrillation-induced-regional-endothelial-dysfunction
#7
YanGuang Li, FuKun Chen, Long Deng, Kun Lin, Xiangmin Shi, Shan Zhaoliang, YuTang Wang
BACKGROUND: Paroxysmal atrial fibrillation (PAF) can increase thrombogenesis risk, especially in the left atrium (LA). The exact mechanism is still unclear. OBJECTIVE: We assessed the effects of PAF on endothelial function, and investigated if febuxostat (FX) can attenuate endothelial dysfunction by inhibition of xanthine oxidase (XO). MATERIALS AND METHODS: Eighteen male New Zealand white rabbits were divided randomly into sham-operated (S), PAF (P) or FX+pacing (FP) groups...
November 11, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27889688/management-of-distal-deep-vein-thrombosis
#8
REVIEW
Helia Robert-Ebadi, Marc Righini
Isolated distal deep vein thrombosis (DVT), also known as calf DVT, represents up to 50% of all lower limb DVT in ultrasound series and is therefore a frequent medical condition. Unlike proximal DVT and pulmonary embolism (PE), which have been extensively studied and for which management is well standardized, much less is known on the optimal management of isolated calf DVT. Recent data arising from registries and non-randomized studies suggest that most distal DVTs do not extend to the proximal veins and have an uneventful follow-up when left untreated...
November 10, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27865967/usual-and-unusual-mutations-in-a-cohort-of-belgian-patients-with-hemophilia-b
#9
LETTER
N Lannoy, C Lambert, A Farrugia, A Van Damme, C Hermans
No abstract text is available yet for this article.
November 10, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27865965/palladin-is-involved-in-platelet-activation-and-arterial-thrombosis
#10
Xuejiao Chen, Xuemei Fan, Juan Tan, Panlai Shi, Xiyi Wang, Jinjin Wang, Ying Kuang, Jian Fei, Junling Liu, Suying Dang, Zhugang Wang
The dynamics of actin cytoskeleton have been shown to play a critical role during platelet activation. Palladin is an actin-associated protein, serving as a cytoskeleton scaffold to bundle actin fibers and actin cross linker. The functional role of palladin on platelet activation has not been investigated. Here, we characterized heterozygous palladin knockout (palladin(+/-)) mice to elucidate the platelet-related functions of palladin. The results showed that palladin was expressed in platelets and moderate palladin deficiency accelerated hemostasis and arterial thrombosis...
November 10, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27837908/does-platelet-count-count
#11
EDITORIAL
Marialaura Bonaccio
No abstract text is available yet for this article.
November 8, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27846449/a-novel-pros1-mutation-c-74dupa-was-identified-in-a-protein-s-deficiency-family
#12
LETTER
Yang Zhang, Hang Yang, Qianlong Chen, Jinxing Yu, Xi Chen, Sheng Liu, Ge Gao, Yunhu Song, Zhou Zhou
Protein S is a vitamin K-dependent plasma glycoprotein that acts as an anticoagulant, and its deficiency usually predisposes individuals to venous thromboembolism. Hereditary protein S deficiency is an autosomal dominant disorder caused by a PROS1 mutation. Herein, we described a novel PROS1 frameshift mutation, c.74dupA, in a hereditary protein S deficiency family. Interestingly, both of the proband and his mother carried the mutation and had a protein S deficiency, however, only the proband suffered a pulmonary embolism while his mother had no history of any thrombosis, suggesting that a triggering event might have been involved in the thrombus formation...
November 6, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27838473/retinal-vein-thrombosis-the-internist-s-role-in-the-etiologic-and-therapeutic-management
#13
REVIEW
Alejandro Garcia-Horton, Fatimah Al-Ani, Alejandro Lazo-Langner
Retinal vein occlusion is a common and important cause of vision loss. In general, knowledge about this condition is scant within an internist's practice but the condition is relevant because of its association with other chronic ailments. A diagnosis of RVO should prompt the investigation of conditions needing chronic management in these patients. In this review we summarize the clinical presentation of RVO, its classification, associated risk factors, and treatment focused in the internist's scope of practice...
November 5, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27837696/genetic-analyses-of-novel-compound-heterozygous-hypodysfibrinogenemia-tsukuba-i-fgg-c-1129-62_65-del-aata-and-fgg-c-1299-4-del-a
#14
Saki Mukai, Kazuhiro Nagata, Minami Ikeda, Shinpei Arai, Mitsutoshi Sugano, Takayuki Honda, Nobuo Okumura
INTRODUCTION: We found a novel hypodysfibrinogenemia designated Tsukuba I caused by compound heterozygous nucleotide deletions with FGG c.1129+62_65 del AATA and FGG c.1299+4 del A on different alleles. The former was deep in intron 8 of FGG (IVS-8 deletion) and the latter in exon 9 of FGG (Ex-9 deletion), which is translated for the γ'-chain, but not the γA-chain. A Western blot analysis of plasma fibrinogen from our patient revealed an aberrant γ-chain that migrated slightly faster than the normal Bβ-chain...
November 5, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27815972/toll-like-receptor-9-expression-and-activation-in-acute-coronary-syndrome-patients-on-dual-anti-platelet-therapy
#15
Kathryn E Hally, Anne C La Flamme, Peter D Larsen, Scott A Harding
INTRODUCTION: The Toll-like receptor 9 (TLR9) pathway can activate platelets but its role in acute coronary syndromes (ACS) is unknown. This study examined TLR9 expression and platelet activation in response to ODN2006, a TLR9 agonist, in healthy subjects and in ACS subjects treated with dual anti-platelet therapy (DAPT). MATERIALS AND METHODS: TLR9 expression was examined in both resting and thrombin receptor activator peptide (TRAP)-activated platelets (1 and 10μM) from healthy and ACS subjects by flow cytometry...
October 29, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27815969/residual-pulmonary-vascular-obstruction-and-recurrence-after-acute-pulmonary-embolism-a-single-center-cohort-study
#16
Benjamin Planquette, Alexis Ferré, Julien Peron, Amandine Vial-Dupuy, Jean Pastre, Gisèle Mourin, Joseph Emmerich, Marie-Anne Collignon, Guy Meyer, Olivier Sanchez
INTRODUCTION: Up to 50% of patients with pulmonary embolism (PE) present lung perfusion defects after six months of anticoagulant treatment, suggesting residual pulmonary vascular obstruction (RPVO). The risk of recurrence in patients with RPVO remains unknown. The present study aims to assess the risk of recurrent venous thromboembolism (VTE) in patients with RPVO after a first symptomatic episode of PE. METHODS: Consecutive patients who survived a first objectively proven acute PE, treated for at least three months with anticoagulants, were included and followed prospectively...
October 29, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27817863/patient-engagement-what-partnering-with-patient-in-research-is-all-about
#17
REVIEW
Lisa Duffett
The inclusion of patients on important decision related to healthcare has marked a significant 'patient revolution' during the last several decades. Patients now played active roles in personal health decisions, healthcare delivery and policy making, and the development of clinical practice guidelines. Such inclusion of patients' values has resulted in largely positive effects. The next wave of this 'patient revolution' is active and meaningful engagement with patients in health related research. Similar to other aspects of healthcare, it is increasingly recognized that experienced patients, their families, and caregivers, have a wealth of knowledge that comes from living and experiencing a medical condition...
October 28, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27815970/granulocyte-colony-stimulating-factor-decreases-the-th1-th2-ratio-in-peripheral-blood-mononuclear-cells-from-patients-with-chronic-immune-thrombocytopenic-purpura-in-vitro
#18
Fei Ge, Zhuo Zhang, Jinxiao Hou, Fenglin Cao, Yingmei Zhang, Ping Wang, Hong Wei, Jin Zhou
Chronic immune thrombocytopenia purpura (ITP) is an autoimmune disease that exhibits an abnormally high Th1/Th2 ratio. Granulocyte colony-stimulating factor (G-CSF) has been shown to decrease the Th1/Th2 ratio in healthy donors. In this study, we investigated the effects of G-CSF treatment on the Th1/Th2 cells and the underlying mechanisms in patients with ITP in vitro. Peripheral blood mononuclear cells (PBMCs) isolated from patients with ITP and healthy controls were treated with G-CSF. Expression levels of interferon (IFN)-γ, interleukin (IL)-2, IL-4, and IL-13 in supernatants were measured by enzyme-linked immunosorbent assays...
October 28, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27835819/stability-of-direct-oral-anticoagulants-in-whole-blood-and-plasma-from-patients-in-steady-state-treatment
#19
LETTER
Rie McGrail, Jesper Revsholm, Peter H Nissen, Erik L Grove, Anne-Mette Hvas
Using functional haemostasis assays, we demonstrated important differences in stability of direct oral anticoagulants (DOACs) in citrated whole blood and plasma from DOAC treated patients. Laboratories and clinicians should take this into consideration and adjust clinical practices accordingly.
October 27, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27821352/regulation-of-plasma-factor-xiii-levels-in-healthy-individuals-a-major-impact-by-subunit-b-intron-k-c-1952-144-c-g-polymorphism
#20
Zoltán A Mezei, Éva Katona, Judit Kállai, Zsuzsanna Bereczky, Éva Molnár, Bettina Kovács, Éva Ajzner, Zsuzsa Bagoly, Tünde Miklós, László Muszbek
BACKGROUND: The regulation of plasma factor XIII (FXIII) levels in healthy individuals has been only partially explored. The identification of major non-genetic and genetic regulatory factors might provide important information on the contribution of FXIII to the risk of cardio/cerebrovascular diseases. OBJECTIVES: To determine the effect of age, smoking, BMI, fibrinogen concentration on plasma FXIII activity, complex FXIII antigen (FXIII-A2B2) and total FXIII-B subunit (tFXIII-B) level, to correlate FXIII-B level with the other two FXIII parameters and to assess the variation of FXIII levels in carriers of major FXIII subunit polymorphisms...
October 27, 2016: Thrombosis Research
journal
journal
22831
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"